Last reviewed · How we verify
Experimental: ALZ-801
ALZ-801 is a small-molecule inhibitor of tau protein aggregation that crosses the blood-brain barrier to reduce pathological tau accumulation in the brain.
ALZ-801 is a small-molecule inhibitor of tau protein aggregation that crosses the blood-brain barrier to reduce pathological tau accumulation in the brain. Used for Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia stage).
At a glance
| Generic name | Experimental: ALZ-801 |
|---|---|
| Also known as | valiltramiprosate, tramiprosate prodrug |
| Sponsor | Alzheon Inc. |
| Drug class | Tau aggregation inhibitor |
| Target | Tau protein |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
ALZ-801 is designed to inhibit the formation and propagation of tau tangles, a hallmark pathology in Alzheimer's disease and other tauopathies. By targeting tau aggregation at the molecular level, the drug aims to slow cognitive decline in patients with early symptomatic Alzheimer's disease. It is an oral prodrug that converts to ALZ-101 in vivo.
Approved indications
- Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia stage)
Common side effects
- Headache
- Diarrhea
- Nausea
- Amyloid-related imaging abnormalities (ARIA)
Key clinical trials
- An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects (PHASE3)
- Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |